Your session is about to expire
← Back to Search
stereotactic body radiation therapy (SBRT) - 47.5 Gy for Prostate Cancer
Study Summary
This trial is testing a new way to give radiation for prostate cancer that may cause less damage to normal tissue.
- Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 94 Patients • NCT00547339Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this trial open to minors or only adults?
"The admission guidelines of this clinical trial stipulate that participants must be 18 years old or older, and no more than 120."
What are the objectives of this clinical experiment?
"This 18-month trial will assess the prevalence of Late Severe Gastrointestinal Toxicity (for Phase 2 Only). Secondary objectives include analyzing Gastrointestinal and Non-Genitourinary Toxicities using the National Cancer Institute Common Toxicity Criteria for Adverse Events, as well as measuring overall survival from date of accession to date of death."
Are there any sites in North America administering this experiment?
"This research is accepting patients from the Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, as well as other centres such as the University of Minnesota Cancer Centre and UC Health Sciences Centre. Additionally, there are 5 more locations that have been added to this clinical trial."
Does my profile meet the criteria for participating in this research project?
"This trial is searching for 94 individuals aged between 18 and 120 with a diagnosis of prostate cancer. Eligible participants must meet the following criteria: T2a or T2b stage, histologically confirmed adenocarcinoma of the prostate, no direct evidence of metastases, Gleason score ≤ 7, PSA ≤ 20 ng/mL (if Gleason 2-6) or 15 ng/mL (if Gleason 7), calculated risk of pelvic lymph node involvement <20%, and an ultrasound estimated volume of the prostate gland not exceeding 60 g."
Is recruitment for this experimental protocol still open?
"The details on clinicaltrials.gov reveal that this research project is not currently enrolling patients. It was originally posted in July 2006 and last updated in March 2022, making it inactive compared to the other 1,321 medical studies actively recruiting participants at present."
Share this study with friends
Copy Link
Messenger